Introduction
============

Chemotherapy is the main treatment approach for advanced gastric cancer and adjuvant post-operative gastric cancer; however, multidrug resistance (MDR) often leads to the failure of chemotherapy ([@b1-ol-0-0-7739]). MDR is a distinct phenomenon enabling tumor cells to simultaneously develop cross-resistance to multiple structurally dissimilar anticancer drugs. Gastric cancer exhibits a strong MDR phenotype, resulting in a response rate to chemotherapy of \<50% ([@b2-ol-0-0-7739]). The 5-year survival rate in advanced gastric cancer is 30%, which is possibly associated with the development of MDR. Therefore, approaches to intervene and reverse MDR in gastric cancer are required to improve the efficacy of chemotherapy and the survival rate of patients with gastric cancer.

Parthenolide (PN) is a sesquiterpene lactone extracted from Feverfew (*Tanacetum parthenium*), and is primarily used for the treatment of fever, arthritis and migraine ([@b3-ol-0-0-7739]). Previous studies have demonstrated that PN inhibits the growth and induces the apoptosis of various tumor cell types *in vitro* ([@b4-ol-0-0-7739]--[@b6-ol-0-0-7739]). Evidence suggests that PN induces anti-tumor effects primarily by targeting nuclear factor-κB (NF-κB) ([@b7-ol-0-0-7739]), producing reactive oxygen species ([@b8-ol-0-0-7739]) and activating c-Jun N-terminal kinase ([@b9-ol-0-0-7739]). Furthermore, previous studies have revealed that PN can enhance gastric, non-small cell lung and liver cancer cell sensitivity to chemotherapy ([@b10-ol-0-0-7739]); however, the underlying mechanisms remain unclear. In the present study, the effects and underlying mechanisms of PN treatment on the sensitivity of drug-resistant gastric cancer SGC-7901/DDP cells to cisplatin (DDP) were investigated, in order to provide a theoretical basis for the clinical application of PN.

Materials and methods
=====================

### Reagents

The reagents and kits used in the present study were purchased as follows: PN (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany); DDP (Shandong Dezhou Taikang Pharmaceutical Co., Ltd., Dezhou, China); RPMI-1640 (Sigma-Aldrich; Merck KGaA); fetal bovine serum (Hangzhou Evergreen Biological Engineering Materials Co., Ltd., Hangzhou, China); Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) detection kit (Nanjing KGI Biological Technology Development Co., Ltd., Nanjing, China); MTT (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China); enhanced chemiluminescence (ECL; GE Healthcare, Chicago, IL, USA); and DAPI (Beyotime Institute of Biotechnology, Haimen, China). The SGC-7901/DDP drug-resistant gastric cancer cell line was purchased from Shanghai Bogoo Biotechnology Co., Ltd. (Shanghai, China). The antibodies were obtained from the following: Goat anti-rabbit and anti-mouse immunoglobulin G secondary antibodies (GE Healthcare Life Sciences, Chalfont, UK); primary antibodies directed against phosphorylated-signal transducer and activator of transcription 3 (p-STAT3), apoptosis regulator Bcl-xL and Bcl-2 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA); β-actin (Sigma-Aldrich; Merck KGaA); and apoptosis regulator BAX (Bax), caspase-3, cleaved caspase-3, cellular tumor antigen p53, caspase-9, cleaved caspase-9, cyclin-dependent kinase inhibitor 1 (p21), cyclin D1 and STAT3 (Wanleibio Biotechnology Co., Ltd., Shanghai, China). Antibodies are detailed in [Table I](#tI-ol-0-0-7739){ref-type="table"}.

### Instruments

General electrophoresis, horizontal and vertical electrophoresis tank, and semi-dry transfer blotter were purchased from Bio-Rad Laboratories, Inc., (Hercules, CA, USA). The Ti-U manual fluorescence/inverted phase contrast microscope was obtained from Nikon Corporation (Tokyo, Japan); BioSpectrum^®^ Imaging system from UVP Inc., (Upland, CA, USA); microplate reader from Tecan Group Ltd. (Männedorf, Switzerland); and Alpha Automatic Image Analysis system from Bio-Techne (ProteinSimple; Minneapolis, MN, USA).

### Cell culture

The human gastric cancer drug-resistant SGC-7901/DDP cell line was cultured in RPMI-1640 supplemented with 10% fetal bovine serum at 37°C with 5% CO~2~.

### MTT assay

MTT was used to measure the effect of PN treatment on SGC-7901/DDP cell proliferation and sensitivity to DDP. SGC-7901/DDP cells in the exponential growth phase were harvested and made into single cell suspensions at a concentration of 5×10^4^ cells/ml. The cells were seeded in 96-well plates (100 µl/well) and incubated for 24 h at 37°C. The SGC-7901/DDP cells were treated with various concentrations of PN (0, 2.5, 5, 10, 12.5 and 15 µmol/l) and DDP (0, 1.25, 2.5, 5, 10 and 15 µg/ml) with five-replicates/concentration. A total of 20 µl of 5 g/l MTT solution was added to each well at 24, 48 and 72 h, and then incubated for 4 h at 37°C. The supernatant was discarded and 150 µl dimethyl sulfoxide was added to each well. The plates were oscillated at a low speed for 2 min at room temperature (23--25°C) until all crystals were fully dissolved. The absorbance of each well was measured at a wavelength of 490 nm using a spectrophotometer. The growth inhibitory rate (%) was calculated using the following formula: (1-(absorbance of experimental well/absorbance of blank)) ×100%.

In order to prevent excessive cell death, based on the results from the above experiments, the combinations of less toxic concentrations of PN (5 and 10 µmol/l) and DDP (1.25 and 2.5 µg/ml) were selected. Therefore, the SGC-7901/DDP cells were treated with the following combinations: 5 µmol/l PN+1.25 µg/ml DDP; 5 µmol/l PN+2.5 µg/ml DDP; 10 µmol/l PN+1.25 µg/ml DDP; or 10 µmol/l PN+2.5 µg/ml DDP. The MTT assay was performed at 24 h following the treatments. The Zhenjun Jin method ([@b11-ol-0-0-7739]) was used to determine the synergy q=E(AB)/(EA+EB-EA × EB) EAB refers to growth inhibitory rate of combined treatment; and EA and EB refer to the growth inhibitory rate with either A or B treatment. q\<0.85 indicates mutual antagonism of two drugs; q=0.85--1.15 indicates a simple additive effect of the two drugs; q\>1.15 indicates that the two drugs have a synergistic effect.

### Cell cycle distribution analysis via flow cytometry

SGC-7901/DDP cells in the exponential growth phase were seeded in 6-cm petri dishes at a density of 5×10^5^ cells/dish. The medium was changed 12 h following seeding and the cells were treated with 0, 7.5 or 15 µmol/l of PN for 48 h at 37°C. The supernatant was discarded and the cells were digested with EDTA-free trypsin, washed twice with PBS, and fixed with 70% ethanol at −20°C overnight. Cell were washed twice with PBS, treated with RNaseA (a final concentration of 250 µg/ml) and incubated in a 37°C water bath for 30 min. The cells were stained with 5 µl PI in a dark room for 50 min at room temperature, and then the cell cycle distribution was measured using a FACSCalibur flow cytometer and FlowJo 7.6.1 (BD Biosciences, Franklin Lakes, NJ, USA).

### Cell apoptosis detection via flow cytometry

SGC-7901/DDP cells in the exponential growth phase were seeded in 6-cm petri dishes at a density of 5×10^5^ cells/dish. After culturing for 12 h, cells were treated with 0, 7.5, or 15 µmol/l PN for 48 h at 37°C. Cells were digested with EDTA-free trypsin, washed twice with PBS, stained for 15 min at room temperature in the dark using the Annexin V-FITC Apoptosis Detection kit and then the apoptosis rate was detected.

### Cell apoptosis was detected by DAPI staining

SGC-7901/DDP cells in the exponential growth phase were seeded in 24-well culture plates at a density of 5×10^4^ cells/well, and cultured for 24 h at 37°C. Cells were treated with 0, 7.5, or 15 µmol/l of PN for 24 h at 37°C. Cells were fixed with 0.1% paraformaldehyde for 30 min, washed with PBS for 5 min and stained with DAPI for 10 min at room temperature (23--25°C). The cells were observed using a fluorescence microscope (magnification, ×100) at an excitation wavelength of 359 nm.

### Western blotting

SGC-7901/DDP cells in the exponential growth phase were seeded in 10 cm dishes at a density of 5×10^5^ cells/ml and cultured for 24 h at 37°C. Cells were treated with different concentrations of PN (final concentration of 0, 7.5 or 15 µmol/l) and collected 48 h after treatment. The total protein was extracted using radioimmunoprecipitation assay buffer (P0013J; Beyotime Institute of Biotechnology) and phenylmethanesulfonyl fluoride (ST506; Beyotime Institute of Biotechnology). The protein quantity was determined using a bicinchoninic acid assay kit (P0011; Beyotime Institute of Biotechnology). Protein samples were boiled at 100°C for 5 min. A total of 30 µg protein/lane was loaded and subjected to SDS-PAGE (10% gel). The proteins were transferred to polyvinylidene difluoride membranes, blocked with 0.5% skim milk for 1 h (23--25°C) and incubated with the appropriate primary antibody at 4°C overnight. The membranes were washed with TBS-Tween 20 three times (5 min/wash) and then incubated with the corresponding secondary antibody at room temperature for 2 h. The membranes were washed with TBST and detected using an ECL luminescent liquid with cytometry. The quantitative analysis was performed with ImageJ software (version 1.45; National Institutes of Health, Bethesda, MD, USA. The relative expression of the target protein was calculated as the ratio of grey values of the target protein to the β-actin internal control.

### Scratch migration assay

SGC-7901/DDP cells in the exponential growth phase were seeded in 6-well plates at a density of 5×10^5^ cells/well and cultured until 70% confluence was achieved. A scratch was made in each well using a 100-µl pipette tip. The cells were treated with various concentrations of serum-free PN (0, 2.5 or 5 µmol/l). Images were acquired at 24, 48 and 72 h after treatment. The scratch width was measured and the mobility was calculated as follows: (Distance/scratch width) ×100%.

### Transwell cell invasion assay

In order to assess the invasive ability of cells, 120 µg Matrigel was added to a Transwell chamber. The gel was diluted with two volumes of serum-free RPMI-1640 and incubated at 37°C for 30 min until the gel solidified. RPMI-1640 containing 10% FBS was added to the lower chamber as a chemoattractant. SGC-7901/DDP cells in the exponential growth phase were digested with EDTA-free trypsin and viable cell counts were performed by eye. A 200-µl suspension containing 5×10^4^ cells was added to each Transwell chamber and cultured for 48 h at 37°C. The experiment was performed in triplicate. The liquid in the upper chamber was discarded. The non-invasive cells and Matrigel on the membrane surface were removed using a wet cotton swab. The membrane was rinsed with saline, slightly dried, fixed in formalin (4%) for 15 min and stained with crystal violet for 12 min (23--25°C). The penetrating cell count was performed in three different fields at a magnification of ×100 using a light microscope.

### Statistical analysis

Data are presented as the mean ± standard deviation. Statistical analysis was performed using SPSS (version 10.0; SPSS, Inc., Chicago, IL, USA) using one-way analysis of variance. Comparisons between groups were measured using the post-hoc test. Multiple comparisons amongst groups were performed using the Student-Newman-Keuls test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Cell proliferation inhibitory effects of PN and the changes in the sensitivity of SGC-7901/DDP to DDP

All concentrations of PN, except 2.5 µmol/l, significantly inhibited SGC-7901/DDP cell proliferation in a time- and concentration-dependent manner compared with untreated cells ([Fig. 1](#f1-ol-0-0-7739){ref-type="fig"}). DDP inhibited SGC-7901/DDP cell proliferation in a similar time- and concentration-dependent manner ([Fig. 2](#f2-ol-0-0-7739){ref-type="fig"}). To investigate the changes in the sensitivity of SGC-7901/DDP cells to the DDP, SGC-7901/DDP cells were treated with combinations of PN and DDP as described above. The rate of proliferation inhibition in each group is presented in [Fig. 3](#f3-ol-0-0-7739){ref-type="fig"}. The q value for each group was calculated using the Zhenjun Jin method. With the exception of the minimal concentration group (5 µmol/l PN+1.25 µg/ml DDP), the q values for all other groups were \>1.15, indicating that the two drugs have a synergistic effect.

### PN induces cell cycle arrest in SGC-7901/DDP cells

SGC-7901/DDP cells were treated with different concentrations of PN (0, 7.5 or 15 µmol/l) and the cell cycle distribution was analyzed 48 h following treatment ([Fig. 4](#f4-ol-0-0-7739){ref-type="fig"}). The ratio of G~0~/G~1~ in the untreated and 7.5, and 15 µmol/l PN groups was 27.2±1.05, 32.7±1.50 and 35.8±1.39%, respectively; the percentage of S-phase cells was 63.98±2.74, 60.49±2.11, and 58.94±3.10%, respectively. Furthermore, the percentage of G~2~/M phase cells was 8.82±0.57, 6.78±0.73 and 4.72±0.46%, respectively. Compared with the untreated control group, the population of S and G~2~/M phase cells in the treatment groups significantly decreased but not significantly, and G~1~ phase cells significantly increased in a concentration-dependent manner (P\<0.05; [Fig. 4](#f4-ol-0-0-7739){ref-type="fig"}).

### PN induces SGC-7901/DDP cell apoptosis

SGC-7901/DDP cells were treated with 7.5 and 15 µmol/l of PN and the cell apoptosis rates were detected 48 h following treatment ([Fig. 5](#f5-ol-0-0-7739){ref-type="fig"}). The early apoptosis rates in the 7.5 and 15 µmol/l treated groups were 6.87±0.63 and 17.7±1.15%, respectively. Compared with the control group (5.30±1.31%), the early apoptosis rate was markedly increased in the 7.5 µmol/l group and significantly increased in the 15 µmol/l group (P\<0.05) compared with that in the untreated control group. The late apoptosis rates were 2.88±0.54, 3.4±0.61 and 4.18±0.78% following no treatment, and treatment with 7.5 and 15 µmol/l PN, respectively. No statistically significant differences were identified between these groups (data not shown).

### PN induces SGC-7901/DDP cell apoptosis as determined using DAPI staining

SGC-7901/DDP cells were treated with 7.5 or 15 µmol/l PN and observed using DAPI staining after 24 h ([Fig. 6](#f6-ol-0-0-7739){ref-type="fig"}). The cells in the untreated control group possessed normally shaped nuclei (round or oval) with uniform staining and evenly distributed nuclear chromatin. The shrinkage, cohesion and fragmentation (spherical or particulate matter) of nuclei were observed 48 h after PN treatment. The number of apoptotic cells increased in a PN concentration-dependent manner, as indicated by the number of dense fluorescent particles ([Fig. 6](#f6-ol-0-0-7739){ref-type="fig"}). The SGC-7901/DDP cell apoptosis rates were 0.88±0.05, 10.56±0.82 and 18.85±1.13% in the untreated, 7.5, and 15 µmol/l PN groups, respectively. The increases in apoptosis rates in the 7.5 and 15 µmol/l groups were significant compared with the untreated control group (P\<0.05; [Fig. 6](#f6-ol-0-0-7739){ref-type="fig"}).

### Expression of apoptosis- and cell cycle-associated proteins

Among the apoptosis-associated proteins, following PN treatment (7.5 or 15 µmol/l) Bax and p53 expression was significantly upregulated, Bcl-xL and Bcl-2 was significantly downregulated, and cleaved caspase-3 and −9 was significantly increased in a dose-dependent manner as compared with the expression in the untreated control groups (all P\<0.05; [Fig. 7](#f7-ol-0-0-7739){ref-type="fig"}). Among the cell cycle-associated proteins, cyclin D1 expression was significantly decreased, p21 was significantly increased, and P-STAT3 activation was significantly inhibited (all P\<0.05; [Fig. 7](#f7-ol-0-0-7739){ref-type="fig"}).

### PN decreases SGC-7901/DDP cell migration

The effect of PN on SGC-7901/DDP cell migration is presented in [Fig. 8](#f8-ol-0-0-7739){ref-type="fig"}. The mobility rate of the untreated control group at 24, 48 and 72 h were 11.85±2.55, 25.57±2.75, and 43.32±2.52%, respectively. The mobility rate of the 2.5 µmol/l PN group at 24, 48 and 72 h were 8.09±0.83, 22.70±2.92, and 31.11±3.85%, respectively. The mobility rate of the 5 µmol/l PN group at 24, 48 and 72h were 3.13±0.76, 7.62±1.17, and 16.54±3.02%, respectively. The differences between the 2.5 and 5 µmol/l PN groups, and the untreated control group at each time point were statistically significant (P\<0.05).

### PN decreases SGC-7901/DDP cell invasion ability

The effect of PN on invasion ability is presented in [Fig. 9](#f9-ol-0-0-7739){ref-type="fig"}. The number of transmembrane cells in the untreated control, and 2.5 and 5 µmol/l PN groups were 737±33.57, 344±12.81, and 127±8.02, respectively. The differences between the treated groups and the untreated control group were statistically significant (P\<0.05).

Discussion
==========

Previous studies have demonstrated that PN can inhibit the proliferation of tumor cells and enhance the sensitivity of certain cancer cell lines to anti-cancer drugs ([@b7-ol-0-0-7739],[@b12-ol-0-0-7739]). Gao *et al* ([@b13-ol-0-0-7739]) suggested that PN enhances the sensitivity of non-small cell lung cancer cells to chemotherapy drugs via modulation of the NF-κB/I-κB kinase (IKK) signal cascade through IKKβ. Furthermore, Liu *et al* ([@b14-ol-0-0-7739]) and another study ([@b15-ol-0-0-7739]) revealed that PN is able to enhance the sensitivity of drug-resistant hepatocellular carcinoma cells to chemotherapy drugs through inhibition of NF-κB activity, the downregulation of P-glycoprotein, multidrug resistance-associated protein, Bcl-2 and proto-oncogene Wnt family member 1 expression levels, and the upregulation of p53 expression. The present study demonstrated that PN significantly inhibited the proliferation of the drug-resistant gastric cancer cell line SGC7901/DDP in a time- and concentration-dependent manner. Additionally, PN and DDP co-treatment demonstrated a synergistic effect. The inhibitory effect of PN on SGC7901/DDP cell proliferation may be due to cycle arrest and the induction of apoptosis. PN treatment was demonstrated to induce early phase apoptosis and G~1~ phase cycle arrest. Furthermore, the results in the present study revealed that the anticancer effects of PN are associated with the upregulation of p53 and Bax, the downregulation of Bcl-2 and Bcl-xL, and the activation of capase-9 and caspase-3. Previously, these proteins have all been demonstrated to be involved in the regulation of apoptosis ([@b12-ol-0-0-7739],[@b16-ol-0-0-7739]), thus these results suggest that PN treatment activates the apoptotic signaling pathway. In addition, the results of the current study revealed that PN significantly decreased cyclin D1, increased p21 expression and inhibited STAT3 activation.

STAT3 in the cytoplasm is a bifunctional protein. Previous studies ([@b17-ol-0-0-7739],[@b18-ol-0-0-7739]) have revealed that the STAT3 downstream target genes, including Bcl-xL, Bcl-2, induced myeloid leukemia cell differentiation protein Mcl-1, cyclin D1, proto-oncogene c-Myc, Jun proto-oncogene AP-1 transcription factor subunit, Fas cell surface death receptor and vascular endothelial growth factor, which are closely associated with cell proliferation, apoptosis, and angiogenesis. Under normal physiological conditions, the activation of STATs is rapid and transient. Sustained activation of this signaling pathway in tumor cells can induce the upregulation of cell cycle regulatory factors and anti-apoptotic proteins, consequently promoting abnormal proliferation, and migration of malignant tumors ([@b19-ol-0-0-7739]). Therefore, STAT3 is considered an oncogene ([@b19-ol-0-0-7739]). Previous studies demonstrated that STAT3 signaling pathway may be associated with tumor cell drug-resistance to chemotherapy ([@b20-ol-0-0-7739],[@b21-ol-0-0-7739]). The aberrant activation of STAT3 can aid in the evasion of cancer cell death caused by drugs, thus inducing drug resistance. The inhibition of the STAT3 signaling pathway may become a potential cancer therapeutic target in the future. For example, Yue *et al* ([@b22-ol-0-0-7739]) demonstrated that the overactivation of STAT3 promotes DDP-resistant ovarian cancer progression, and can be used as a gene marker for drug resistance and cancer recurrence. Ovarian cancer cells with high expression levels of STAT3 and Bcl-xL exhibit DDP, and Taxol resistance; whereas, low STAT3 expression cell lines are sensitive to the drug treatment ([@b23-ol-0-0-7739]). Inhibiting the STAT3 signaling pathway can promote apoptosis of drug-resistance cancer cells and increase the sensitivity of cancer cells to various drugs ([@b23-ol-0-0-7739]). In addition, a previous study demonstrated that STAT3 activation-induced expression of Bcl-xL can enhance the survival and drug resistance capability of human tumor cells; and that silencing of the STAT3 gene downregulates the expression of Bcl-xL ([@b24-ol-0-0-7739]). In addition, inhibition of Bcl-xL protein expression through siRNA knockdown in the gastric cancer MGC-803 cell line promotes programmed cell death ([@b24-ol-0-0-7739]).

STAT3 overactivation has been identified in various types of tumor cells, including breast and ovarian cancer, and head and neck squamous cell carcinoma ([@b25-ol-0-0-7739],[@b26-ol-0-0-7739]). In addition, Yu *et al* ([@b27-ol-0-0-7739]) demonstrated that the activity of STAT3 in gastric cancer cell lines is higher compared with that in normal gastric epithelial cells. STAT3-DNA binding activity is higher in poorly differentiated gastric adenocarcinoma cell lines (SGC7901, MKN45 and AGS) compared with in highly differentiated gastric cancer cell lines (MKN28 and NCI-SNU-1) ([@b27-ol-0-0-7739]). Furthermore, p-STAT3 expression in poorly differentiated gastric cancer tissue is higher compared with in the adjacent normal mucosa, suggesting that the overactivation of STAT3 serves a role in gastric cancer ([@b27-ol-0-0-7739]).

The results of the present study revealed that PN significantly inhibited STAT3 phosphorylation, modulated the expression levels of the downstream cell cycle-associated proteins, including cyclin D1 and p21, and downregulated the apoptosis-associated protein expression, including Bcl-2 and Bcl-XL. Cyclin D1 is an essential protein in the regulation of the cell cycle G~1~ phase. p21 is an important member of the cell cycle protein kinase inhibitor gene family. Decreased cyclin D1 and increased p21 expression results in increased cell cycle arrest at the G~1~ phase. Bcl-2 and Bcl-xL are important members of the anti-apoptotic protein family. Bcl-2 and Bcl-XL downregulation can enhance tumor cell susceptibility to drug-induced apoptosis. Song *et al* ([@b28-ol-0-0-7739]) revealed that PN inhibits the activation of STAT3 signaling pathway; Carlisi *et al* ([@b29-ol-0-0-7739]) also demonstrated that PN significantly reduces STAT3 and STAT5 phosphorylation, and increases the sensitivity of liver cells to apoptosis. Cheng *et al* and Ghantous *et al* ([@b30-ol-0-0-7739]--[@b32-ol-0-0-7739]) also confirmed that the anti-tumor effects of PN are not only due to the inhibition of NF-κB, but also associated with p21 upregulation, and the downregulation of cyclin D1 and Bcl-xL. The results of the current study are consistent with these previous studies. However, STAT3 converges various carcinogenic kinase signaling pathways, including the epidermal growth factor, interleukin-6/Janus kinase and Src signaling pathways. The mechanisms underlying the interactions of PN with the upstream and downstream factors in these complex signaling pathways warrants further investigation. In addition, the present study revealed that PN can inhibit SGC7901/DDP cell migration and invasion. These results suggest that PN is a promising anticancer drug for the treatment of patients with gastric cancer.
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![Proliferation inhibition rate of SGC-7901/DDP cell 24 h following combined treatments of PN and DDP. The Zhenjun Jin method was used to determine the synergy (q). With the exception of the minimal concentration group (5 µmol/l PN+1.25 µg/ml DDP), the q values for all other groups were \>1.15, indicating that the two drugs have a synergistic effect. DDP, cisplatin; PN, parthenolide.](ol-15-03-3572-g02){#f3-ol-0-0-7739}
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![Effect of parthenolide (7.5 or 15 µmol/l) on SGC-7901/DDP cell apoptosis using flow cytometry. \*P\<0.05 compared with untreated control group.](ol-15-03-3572-g04){#f5-ol-0-0-7739}

![Effect of PN (7.5 or 15 µmol/l) on SGC-7901/DDP cell apoptosis via DAPI detection with fluorescence microscopy (magnification, ×100). \*P\<0.05 compared with untreated control group.](ol-15-03-3572-g05){#f6-ol-0-0-7739}

![Effect of PN (7.5 or 15 µmol/l) on the protein expression levels of apoptosis- and cell cycle-associated proteins in SGC-7901/DDP cells using western blotting. \*P\<0.05; ^\#^P\<0.01 compared with untreated control group. p-STAT3, phosphorylated-signal transducer and activator of transcription 3; Bcl-xL, apoptosis regulator Bcl-xL; Bcl-2, apoptosis regulator Bcl-2; Bax, apoptosis regulator BAX; p53, cellular tumor antigen p53; p21, cyclin-dependent kinase inhibitor 1.](ol-15-03-3572-g06){#f7-ol-0-0-7739}

![Effect of PN (2.5 or 5 µmol/l) on SGC-7901/DDP cell migration using a Scratch migration assay (magnification, ×100). \*P\<0.05; ^\#^P\<0.01 compared with untreated control group.](ol-15-03-3572-g07){#f8-ol-0-0-7739}

![Effect of PN (2.5 or 5 µmol/l) on SGC-7901/DDP cell invasion ability using a Transwell invasion assay (magnification, ×100). \*P\<0.05 compared with untreated control group.](ol-15-03-3572-g08){#f9-ol-0-0-7739}

###### 

Antibodies.

  Antibody target   Supplier                                          Catalog no.   Dilution
  ----------------- ------------------------------------------------- ------------- ----------
  p-STAT3           Santa Cruz Biotechnology, Inc., Dallas, TX, USA   Sc-293059     1:100
  Bcl-xL,           Santa Cruz Biotechnology, Inc.                    Sc-7195       1:300
  Bcl-2             Santa Cruz Biotechnology, Inc.                    Sc-509        1:300
  β-actin           Sigma-Aldrich; Merck KGaA, Darmstadt, Germany     SAB2100037    1:300

Bcl-xL, B cell lymphoma extra-large; p-STAT, phosphorylated signal transducer and activator of transcription.
